News & Press Releases

Press Releases

November 7, 2017

Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018

Augmenix, Inc announced today that the American Medical Association (AMA) established a new Current Procedural Terminology (CPT®) code, 55874, for periprostatic implantation of biodegradable material, under which SpaceOAR hydrogel will be typically billed.
Us Too
September 28, 2017

Augmenix Partners with Us TOO International to Stream Live Webcast and Q & A on Prostate Cancer Radiation Therapy

Together with Us TOO International, a nonprofit organization committed to improving the lives of those affected by prostate cancer, we held a live webcast for prostate cancer patients and their caregivers on Monday, October 2, from 7:15 pm – 9:00 pm EST.
September 26, 2017

Positive Clinical Trial Results Demonstrating Efficacy of SpaceOAR® Hydrogel in Patients Undergoing SBRT for Prostate Cancer

Application of SpaceOAR hydrogel significantly reduces rectal injury in a high-dose SBRT treated patient population
September 20, 2017

Augmenix to Unveil New Clinical Data on its Innovative Absorbable Hydrogel Technology at the 59th Annual Meeting of the American Society for Radiation Oncology

Augmenix will have a significant presence at ASTRO 2017. Most notably, results from the first prospective study evaluating the efficacy of SpaceOAR hydrogel in patients undergoing high-dose stereotactic body radiation therapy (SBRT) for prostate cancer.
September 6, 2017

Augmenix Announces Positive Five-Year Long-Term Data Highlighting Significant Bowel and Sexual Quality of Life Benefits for Prostate Cancer Patients Treated with SpaceOAR® Hydrogel

Long-term results recently published in the International Journal of Radiation Oncology Biology and Physics confirm the continued benefit of rectal spacing previously reported three-year follow-up results.
August 29, 2017

NICE Announces Interventional Procedure Guidance Supporting Use of Hydrogel Spacer in Treatment of Prostate Cancer in the UK

The National Institute for Health and Care Excellence (NICE) in the UK has issued Interventional Procedure Guidance (IPG) supporting the use of a hydrogel barrier to reduce the risk of toxicity to surrounding tissue in radiotherapy to treat prostate cancer.
August 23, 2017

Augmenix, Inc. Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR® Hydrogel

Palmetto GBA, LLC, the Medicare Administrative Contractor (MAC) covering North Carolina, South Carolina, Virginia and West Virginia will establish coverage for SpaceOAR® hydrogel when medically necessary, effective October 2, 2017.
August 22, 2017

Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year

Augmenix Maintains Spot in Top 10% of Metro-Boston Companies; Three-Year Growth over 2,000% Ranked Company Number 207 on Inc. Magazine’s Top 500
June 28, 2017

Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR® Hydrogel in Israel

The Chaim Sheba Medical Center now offers the hydrogel spacer to reduce side-effects during prostate cancer radiation therapy.
June 26, 2017

The First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in New Zealand

Kathleen Kilgour Centre is the first cancer center in New Zealand to offer this innovative product to their community.
May 31, 2017

SpaceOAR System Receives Shonin Approval in Japan

Augmenix has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its SpaceOAR® System in Japan.
May 2, 2017

Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in Canada

Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, today announced that the first patient in Canada has been treated with SpaceOAR hydrogel at the Princess Margaret Cancer Centre, University Health Network, Toronto. SpaceOAR hydrogel is the first absorbable spacer designed to separate the rectum and prostate to reduce the risk of rectal toxicity during radiotherapy. Princess Margaret will also initiate a 20-patient pilot study to assess the use of SpaceOAR hydrogel in the treatment of prostate cancer.
March 6, 2017

Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment

An abstract accepted at the ASCO 2017 Genitourinary Cancer Symposium showed that SpaceOAR hydrogel, placed between the prostate and rectum in men undergoing prostate radiotherapy, helps men maintain sexual function and potency following intensity modulated radiation therapy (IMRT).
January 11, 2017

Augmenix Announces Positive Three-Year Long-Term Data Highlighting Benefits of SpaceOAR® Hydrogel Spacer for Patients with Prostate Cancer

Results published in the International Journal of Radiation Oncology Biology and Physics show on average no long-term declines in bowel and urinary quality of life for patients and 78% reduction in late rectal toxicity. (Business Wire)
December 21, 2016

Augmenix To Present at the 35th Annual J.P. Morgan Healthcare Conference

Augmenix, Inc. will participate in the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco. John Pedersen, Chief Executive Officer, is scheduled to present on Thursday, January 12, 2017 at 9:30 a.m. Pacific Time in the Elizabethan D room.
November 17, 2016

Augmenix to Present at the Annual Piper Jaffray Healthcare Conference on Wednesday, November 30

Augmenix, Inc. today announced that it will present at the Piper Jaffray 28th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, November 30, 2016. John Pedersen, Chief Executive Officer is scheduled to present at 1:10 p.m. Eastern Time.
November 16, 2016

Augmenix named as one of the 140 companies defining the medical device industry by CB Insights

The Periodic Table Of Medical Device Startups is meant to serve as a guide to navigate the key players in the space. The 140 companies and 10 investors in the table were chosen using CB Insights data on total funding received by each company, number of investors’ unique investments in the category, and exits data.
November 9, 2016

Augmenix Announces New Category 1 CPT® Code from the American Medical Association for Periprostatic Implantation of Biodegradable Material

With the support of the American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA), the American Medical Association (AMA) has granted a Category I, Current Procedural Terminology (CPT) code specifically for periprostatic implantation of biodegradable material. The CPT Code establishes a standard reimbursement pathway for this new procedure which is performed with SpaceOAR® technology.
September 27, 2016

Augmenix Announces Positive SpaceOAR® Clinical Trial Results Demonstrating Superior Outcomes at 3-Years

WALTHAM, Mass.--(BUSINESS WIRE)--Today Augmenix, Inc. (, a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, announced the 3-year results from the SpaceOAR System Prostate Cancer US Pivotal Clinical Trial. These results were presented at the 2016 American Society for Radiation Oncology Annual Meeting in Boston, MA as a Late Breaking Abstract, an honor reserved for highly significant and timely findings in clinical oncology, radiobiology or medical physics. Entitled “Continued Benefit to Rectal Separation for Prostate RT: Final Results of a Phase III Trial”, the study results presented by Daniel Hamstra, MD, PhD, a radiation oncologist at Texas Oncology in Irving, TX demonstrated significantly lower rectal toxicity and higher patient quality of life (QOL) scores when the SpaceOAR System was applied prior to radiotherapy as compared to the trial control patients.
August 18, 2016

Augmenix Ranked as One of America’s Fastest-Growing Private Companies

With a Three-Year Sales Growth of 643%, Augmenix is one of the Fastest Growing Private Companies as Recognized by Inc. Magazine. Augmenix is ranked in the top 12% in BusinessWire's 35th annual Inc. 5000, the most prestigious ranking of the nation's fastest-growing private companies.
July 13, 2016

Augmenix Financing Will Enable Sales Growth

Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced it secured $6 million in series E funding from existing investors. This infusion of capital will allow Augmenix to focus on next-generation products and build on significant growth driven by the robust commercial uptake of its innovative SpaceOAR® System.
June 11, 2015

Augmenix Announces Publication of SpaceOAR® System Clinical Trial Results in Leading Radiation Oncology Journal

Pivotal Study Demonstrates Product Safety and Patient Benefits in Men Undergoing Prostate Radiotherapy
October 16, 2009

Augmenix, Inc. Closes $6.1 Million Financing

(PR Newswire)
July 24, 2009

Startup Augmenix Seals Up $4.7M in Funding

(Mass High Tech)